RAMM Pharma Corp. (CSE: RAMM) is an innovative leader in the field of cannabinoid pharmacology and product formulation, specializing in cannabis-based pharmaceuticals and related healthcare products. The company leverages a unique and diversified international production and sales platform to supply expanding global medical markets with standardized, plant-derived therapeutic solutions.
The company’s operations are anchored by an established pharmaceutical and medical product business in Uruguay, which has successfully developed several medically registered plant-derived cannabinoid pharmaceuticals. These products are fully authorized for commercial sale and compassionate use across multiple Latin American countries. Utilizing its state of the art, good manufacturing practice certified formulation facility in Montevideo, Uruguay, RAMM is actively advancing a pipeline of new products, including registered cannabis-based nutrition and specialized veterinary products in various stages of development and approval.
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES TORONTO, May 30, 2019 (GLOBE NEWSWIRE) -- Further to its news release dated May 3, 2019 announcing the proposed acquisition...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES TORONTO, May 03, 2019 (GLOBE NEWSWIRE) -- MTC Growth Fund-I Inc (“MTC” or the “Corporation”) is pleased to...